novo nordisk semaglutide shortage Ozempic's patent problem: how lost control of a blockbuster drug. 💉 Demand for GLP-1 weight-loss drugs has exploded, turning Ozempic into a $40bn+ revenue engine for Novo Nordisk. But, despite Novo takes big step toward

From a metabolic health perspective, treating insulin resistance before it progresses to diabetes makes sense

A randomized controlled trial indicated that curcumin supplementation resulted in significant improvements in liver enzyme levels and histological features of liver steatosis among patients with NAFLD, underscoring its therapeutic potential

While these drugs are a tool, it becomes important to consider who has access to them and the nature of support and care offered to patients taking the medication

Twenty microliters of each sample, including 2% w/w of sodium lauryl sulfate solution as a positive control, DI water as a negative control, the hydrogel placebo, and the hydrogel containing extract, was placed on the skin using a Finn chamber (Smart Practice, Phoenix, Arizona) and kept in position for 24 hours

Semaglutide hits one receptor, Tirzepatide hits two, and Retatrutide hits three and in published trials Retatrutide has produced the largest reductions of the group